Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that the company's founder and CEO, Alex Zhavoronkov, PhD, again was recognized in the Highly Cited Researchers of (IMAGE)

InSilico Medicine

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that the company's founder and CEO, Alex Zhavoronkov, PhD, again was recognized in the Highly Cited Researchers of

Caption

The distinction of Highly Cited Researchers is an important indicator for the impact of a researcher’s scientific publications, which indicates their publications rank cumulatively among the top 1% in their fields and publication years. 6,636 researchers from more than 1,200 institutions in 59 nations and regions have been recognized this year.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.